The role of cholecystokinin (CCK) in pancreatic growth and secretory development in fetal and neonatal guinea pigs was investigated by CCK receptor blockade. For the last 20 days of gestation, sows received the CCKA receptor antagonist, MK329 (25 nmol/kg/h) by continuous subcutaneous infusion. Alternatively, neonates from untreated females received an MK329 infusion for the first 4 or 15 days following birth. Pancreatic weight, DNA, RNA, protein, and amylase content per 100 g body weight and secretory responses to CCK, car-bamylcholine, and phorbol ester were determined at birth and 4 days in animals receiving MK329 in utero and were measured at 4 and 15 days in neonatally infused animals.No significant changes in pancreatic growth parameters were seen in MK329-treated animals compared to controls, except for a small (14%; p < 0.02) decrease in weight after 15 days of neonatal exposure. Enhanced amylase secretion in response to CCK and carbamylcholine was seen in all groups receiving MK329 (all p values < 0.00001). Pancreatic growth and secretion were not inhibited by CCKA receptor blockade, which suggests that the effects of CCK mediated by the CCKA receptor are not essential for growth or development of the pancreatic amylase secretory response in the neonatal guinea pig.
- Pancreatic development
- Pancreatic secretion
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism